PDF(Pubmed)
Abstract：
Urticaria is a disease triggered by mast cells and characterized by recurrent symptoms such as wheals and/or angioedema. Most patients benefit from treatment with antihistamines (AH) or, if not effective enough, from additional therapy with omalizumab, which leads to significant symptom relief. Here we present a patient with therapy-resistant chronic spontaneous urticaria treated with AH, omalizumab, and glucocorticosteroids. The subsequent recommended therapy according to the current guideline, cyclosporine A, was contraindicated in this patient. Therefore, therapy with dupilumab was initiated, resulting in a complete control of symptoms. In this case report, we present a case of successful dual therapy with omalizumab and dupilumab.
摘要：
荨麻疹是由肥大细胞引发的疾病，其特征是反复出现的症状，例如风团和/或血管性水肿。大多数患者受益于抗组胺药（AH）或，如果不够有效，来自奥马珠单抗的额外治疗，这导致了显著的症状缓解。在这里，我们介绍了用AH治疗的治疗抗性慢性自发性荨麻疹的患者，奥马珠单抗，和糖皮质激素.根据当前指南的后续推荐治疗，环孢菌素A,这个病人是禁忌的。因此,开始使用dupilumab治疗，从而完全控制症状。在这个案例报告中,我们介绍了一例奥马珠单抗和dupilumab双重治疗成功的病例.
